Some Women Choosing Unnecessarily Radical Surgeries for Early-Stage Cancer

New Study Finds Low Risk of Contralateral Breast Cancer Does Not
Justify Bilateral Mastectomy for DCIS Patients

Abstract: Contralateral breast cancer (CBC) risk in women with
ductal carcinoma in situ (DCIS): Is it high enough to justify bilateral
mastectomy?

LAS VEGAS–(BUSINESS WIRE)–#ASBrS17–Women with ductal carcinoma in situ (DCIS), an early, non-invasive
cancer, who choose surgical removal of both breasts (bilateral
mastectomy) to reduce the risk of developing a second cancer in the
opposite (contralateral) breast may be over-treated for their disease,
suggests new research presented this week at the Annual Meeting of the
American Society of Breast Surgeons. A study of 2,750 DCIS patients who
underwent breast-conserving lumpectomy surgery found that only 2.8%
developed a second contralateral cancer after five years, while only
5.6% did so after 10 years.

Perhaps surprisingly, younger age, positive family breast cancer
history, higher nuclear grade disease, clinical presentation and earlier
treatment timeframe did not correlate with development of new,
contralateral tumors. However, many of these factors were associated
with cancer returning in the same (ipsilateral) breast. Overall, an
ipsilateral recurrence was more than twice as likely as development of a
new cancer in the opposite breast.

“A rapidly growing number of women are choosing double mastectomies for
DCIS, perhaps because they misperceive their risk of future cancer. Our
research provides important data for treatment decision-making,”
explains lead study author Megan Miller, M.D., Breast Surgical Oncology
Fellow, Memorial Sloan Kettering Cancer Center. “It suggests patients
and their doctors should focus on risk factors and appropriate therapy
for the diseased breast, not the opposite breast, and that ipsilateral
DCIS should not prompt a bilateral mastectomy.” . . .Cont.

https://www.breastsurgeons.org/news_releases_2017.php

LINK TO FULL PRESS KIT FROM AMERICAN SOCIETY OF BREAST SURGEONS ANNUAL
MEETING PRESS CONFERENCE, WITH FULL RELEASE AND ADDITIONAL PRESS
RELEASES ON:

  • Debunking the Myth of Lymphedema Risk
  • Contemporary Inflammatory Breast Cancer Therapy Yields Low
    Local/Regional Recurrence

Contacts

HealthFlash Marketing
Molly McDougall, 203-431-4000
molly@healthflashmarketing.com